Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health, Inc. (TDOC) officer Kelly Bliss, President, U.S. Group Health, reported vesting and settlement of equity awards and a related sale. On September 1, 2026, she converted 15,311 restricted and performance stock units into the same number of Teladoc common shares. On September 2, 2026, she sold 7,357 common shares at $6.301 per share, with the company stating the sale was to cover tax withholding obligations arising from the vesting of her stock unit awards. Following these transactions, she continues to hold 7,798 performance stock units directly.
Teladoc Health, Inc. (TDOC) reports that Chief Accounting Officer Joseph Ronald Catapano settled equity awards and a related tax sale. On September 1, 2026, he converted 833 restricted stock units and 39 performance stock units into the same number of TDOC common shares on a one-for-one basis. On September 2, 2026, he sold 274 common shares at $6.301 per share, with the company stating this sale was to cover the tax withholding obligation arising from the vesting of these awards. Following the September 1 transactions, 5,001 restricted stock units and 232 performance stock units remained outstanding. No Rule 10b5-1 trading plan is indicated.
Teladoc Health, Inc. (TDOC) reported that Chief Executive Officer and director Charles DiVita III had restricted and performance stock units vest into common stock and sold a portion of shares. On September 1, 2026, 42,277 restricted stock units and 1,966 performance stock units converted one-for-one into common shares. On September 2, 2026, 18,327 common shares were sold at $6.30 per share to cover tax withholding obligations related to these vestings. No Rule 10b5-1 trading plan is reported for these transactions.
Teladoc Health, Inc. (TDOC) reports that Fernando M. Rodrigues, President of BetterHelp, converted a total of 15,251 restricted stock units into an equal number of common shares on September 1, 2026, then sold 15,251 common shares on September 2–3, 2026. One sale covered tax withholding on RSU vesting and another was executed under a Rule 10b5-1 trading plan adopted on November 3, 2025.
Teladoc Health, Inc. (TDOC) is the issuer for a planned sale of common stock reported under Rule 144 by officer Fernando Madeira Rodrigues. The notice covers up to 9,812 shares of common stock, to be sold through Fidelity Brokerage Services LLC.
The filing also lists prior sales of Teladoc common stock by Fernando Madeira Rodrigues during the past three months, including transactions on June 3, 2026 and September 2, 2026, with total reported proceeds in the tens of thousands of dollars.
Teladoc Health, Inc. (TDOC) discloses a planned sale of its common stock under Rule 144 by officer Kelly M. Bliss. A total of 7,357 shares are planned to be sold through Fidelity Brokerage Services LLC, with an indicated aggregate market value of $46,358.67 as of September 2, 2026.
The shares were acquired on September 1, 2026 through restricted stock vesting as compensation, and the sale includes shares needed to cover a tax obligation arising from settlement of a vested equity award distribution. The notice also lists several prior sales of Teladoc common stock by Kelly M. Bliss during the preceding three months.
Teladoc Health, Inc. (TDOC) received a Rule 144 notice that officer Fernando Madeira Rodrigues intends to sell 5,439 shares of common stock through Fidelity Brokerage Services LLC on the NYSE. The shares relate to restricted stock vesting on September 1, 2026, with part of the sale covering tax obligations from the equity award settlement.
The notice also lists prior sales by Rodrigues over the past three months totaling 15,249 shares of common stock for an aggregate of $114,131.29.
Teladoc Health, Inc. (TDOC) is the issuer for a planned sale of its common stock reported under Rule 144 on behalf of officer Adam Vandervoort. The notice covers up to 7,573 shares of common stock to be sold through Fidelity Brokerage Services LLC on the NYSE, with a reported aggregate market value of $47,719.74. The securities to be sold arise from a restricted stock vesting on September 1, 2026, and the filer states that the sale includes an amount necessary to cover a tax obligation from the settlement of a vested equity award distribution. Over the prior three months, Vandervoort reported selling 7,906 shares of Teladoc common stock for an aggregate value of $60,299.06.
Teladoc Health, Inc. (TDOC) is the issuer in a Form 144 notice filed for planned sales of its common stock by officer Carlos Nueno. The notice covers a planned sale of 6,200 shares of common stock through Fidelity Brokerage Services LLC on the NYSE.
The securities to be sold arise from restricted stock vesting on September 1, 2026, characterized as compensation from the issuer. A prior sale of 6,196 shares in the last three months is also disclosed. The filer notes that the sale includes shares needed to cover a tax obligation from settlement of a vested equity award.
Teladoc Health, Inc. (TDOC) is the issuer for which Charles Divita III has filed a notice of proposed sale of restricted shares under Rule 144. The notice covers the potential sale of 18,327 shares of common stock through Fidelity Brokerage Services LLC, with an approximate aggregate market value of $115,483.92 as of September 2, 2026 on the NYSE. The shares to be sold arise from restricted stock vesting on September 1, 2026 and are characterized as compensation from the issuer, with a portion of the sale intended to cover a tax obligation from the vested equity award.